Economic and Quality Advantages of the EZ-IO
» The True Cost of Vascular Access
» A Complete Solution
» Multiple Care Settings
» Quality and Risk Management
» Environmentally Responsible & Cost-Effective Waste
» A Proven Partner
The True Cost of Vascular Access.
Central lines are costly, even without additional costs related to infections and other complications. While central lines can be an important component of critical care management, many central lines are placed simply due to the lack of vascular access. Intraosseous (IO) access requires significantly less equipment and personnel resources than central venous catheters. Utilizing the IO Option, hospitals have the potential for substantial savings by using intraosseous access to replace unnecessary central lines. Moreover, with increased CMS emphasis on hospital-acquired conditions (HAC’s), the IO Option can result in lower CVL use and associated costs, lower CVL complications and non-reimbursable conditions. Additional potential benefits:
- Improved Emergency Department throughput
- Improved door-to-drug times
- Lower number of unnecessary admissions to intensive care
- Improved bed utilization and length of stay
- Improved efficiency and resource management
Contact us at cvl@vidacare.com to request additional detail on cost savings.
A Complete Solution.
Adoption of the EZ-IO Vascular Access System includes the following support:
- Comprehensive training package, including:
- Personal on-site training with expert clinical staff
- Ready-to-use training presentations
- On-line training
- Ongoing clinical support
- 24-hour clinical support line: 1.800.680.4911
- Sample protocol/policies and procedures
- Competency tests and checklists
- Annotated bibliography of IO research
Multiple Care Settings.
Rapid vascular access can be critical in a variety of clinical settings:
- Emergency Department
- Critical Care Unit
- Rapid Response/Code Teams
- Anesthesiology
- Surgical and Perioperative Areas
- Interventional Radiology/Special Procedures
Quality and Risk Management.
Historically, intraosseous research has reported very low complication rates of less than 1%.1 The vast majority of these complications are minor, such as extravasation and needle removal issues. Even with older-generation IO technology, very rare cases of osteomyelitis have been reported.1 However, with EZ-IO technology, these complications are even more rare. These rates are especially insignificant when compared with the most common complications of central venous catheters, (bloodstream infections, arterial puncture, pneumothorax, thrombus).
Environmentally Responsible & Cost-Effective Waste.
EZ-IO needles are 2-3 inches long, and weigh a mere 0.2 ounces, compared to larger IO devices that weigh between 2–5 ounces. With a smaller environmental footprint than any other IO device, the EZ-IO creates minimal medical waste and less hazardous waste costs for the hospital.
A Proven Partner.
- 350,000 insertions worldwide
- 350 insertions per day
- 10 seconds per insertion
Established in 2001, Vidacare Corporation (maker of the EZ-IO®) is the leading developer, manufacturer and marketer of advanced intraosseous access technology for multiple diagnostic and therapeutic applications. Vidacare products are marketed in over 50 countries worldwide.
1 Rossetti VA, Thompson BM, Miller J, Mateer JR, Aprahamian C. Intraosseous infusion: an alternative route of pediatric intravascular access. Ann Emerg Med 1985; 14:885-8.
